Indeed, an analysis from the GOAL study evidenced significantly reduced AA and PGE2 levels but not the rescue of LA and DHA deficiency in individuals with CF under ivacaftor [117], suggesting that CFTR correction could partially mitigate some aspects of the aberrant AA-derived inflammatory responses. This evidence concerns the gene CFTR and cystic fibrosis.